RxDoctor Payments DataLook up a doctor →

Mariah Cox, NP

Nurse Practitioner · Gulfport, MSNPI 1760941223

Payments from drug & device makers

$14,022in general payments, 2019–2025

Across 529 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Novartis$1K
  • Boston Scientific$1K
  • Boehringer Ingelheim$929
  • Actelion Pharmaceuticals US, Inc.$684
  • E.r. Squibb & Sons, L.L.C.$675
  • plus $5K from 27 others

What the payments were for

  • Travel & lodging$3,60626%
  • Food & beverage$10,35274%
  • Education$640%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,022 in reported general payments places this provider in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$682
Medicare patients
11
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban274$242,630
EntrestoSacubitril/Valsartan144$167,288
Repatha SureclickEvolocumab67$77,574
XareltoRivaroxaban71$76,489
JardianceEmpagliflozin25$30,267
Praluent PenAlirocumab20$25,786
FarxigaDapagliflozin Propanediol18$16,947
BrilintaTicagrelor16$9,665
Clonidine57$5,140
Metoprolol Succinate286$3,271
Midodrine Hcl43$2,848
Rosuvastatin Calcium283$2,652
Valsartan115$2,541
Ezetimibe137$2,344
Ranolazine ErRanolazine42$2,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$595$242,630274 claims
NovartisEntresto$1,378$167,288144 claims
Johnson & JohnsonXarelto$596$76,48971 claims
Boehringer IngelheimJardiance$929$30,26725 claims
AstraZenecaFarxiga, Brilinta$98$26,61234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →